Here at Beauhurst, we track equity investment in UK companies. We know that a lot of young businesses use equity finance to fuel their growth, so we treat it as a key indicator of their potential. We’ve selected a cohort of startup companies that raised equity finance in 2011. 893, to be exact. By tracking this select cohort, we’ve had a chance to examine their progress in detail.
Success stories
15% of the businesses we examined have exited, meaning they’ve either been listed on a stock exchange or sold.
IPOs
Of the 2011 cohort, 18 companies (2%) floated on public stock exchanges, predominantly AIM. The two largest IPOs, however, were on to the LSE main board. Between them, these 18 companies raised a total of £940m across their initial public offerings.
It will come as no surprise that all but two of the companies were strongly technology-based. More strikingly, however, a third of the companies that listed were operating in the life sciences space. As drug development processes are extremely capital intensive, it makes sense that these businesses would turn to public markets, rather than individuals or venture capital funds, for the backing they need.











